These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 24175223)

  • 1. Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma.
    Chen LP; Zhao J; Du Y; Han YF; Su T; Zhang HW; Cao GW
    World J Virol; 2012 Dec; 1(6):174-83. PubMed ID: 24175223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk for hepatocellular carcinoma in the course of chronic hepatitis B virus infection and the protective effect of therapy with nucleos(t)ide analogues.
    Rapti I; Hadziyannis S
    World J Hepatol; 2015 May; 7(8):1064-73. PubMed ID: 26052395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. INASL Position Statements on Prevention, Diagnosis and Management of Hepatitis B Virus Infection in India: The Andaman Statements.
    Arora A; Singh SP; Kumar A; Saraswat VA; Aggarwal R; Bangar M; Bhaumik P; Devarbhavi H; Dhiman RK; Dixit VK; Goel A; Goswami B; Kapoor D; Madan K; Narayan J; Nijhawan S; Pandey G; Rai RR; Sahu MK; Saraf N; Shalimar ; Shenoy T; Thomas V; Wadhawan M;
    J Clin Exp Hepatol; 2018 Mar; 8(1):58-80. PubMed ID: 29743798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of chronic hepatitis B virus infection - Dutch national guidelines.
    Buster EH; van Erpecum KJ; Schalm SW; Zaaijer HL; Brouwer JT; Gelderblom HC; de Knegt RJ; Minke Bakker C; Reesink HW; Janssen HL;
    Neth J Med; 2008; 66(7):292-306. PubMed ID: 18663260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of HBV therapy on the incidence of hepatocellular carcinoma.
    Triolo M; Della Corte C; Colombo M
    Liver Int; 2014 Feb; 34 Suppl 1():139-45. PubMed ID: 24373091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virological response to entecavir reduces the risk of liver disease progression in nucleos(t)ide analogue-experienced HBV-infected patients with prior resistant mutants.
    Yang SC; Lee CM; Hu TH; Wang JH; Lu SN; Hung CH; Changchien CS; Chen CH
    J Antimicrob Chemother; 2013 Sep; 68(9):2154-63. PubMed ID: 23620466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis.
    Wang X; Liu X; Dang Z; Yu L; Jiang Y; Wang X; Yan Z
    Gut Liver; 2020 Mar; 14(2):232-247. PubMed ID: 31158948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of chronic hepatitis B: case selection and duration of therapy.
    Leung N
    J Gastroenterol Hepatol; 2002 Apr; 17(4):409-14. PubMed ID: 11982721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Addition of nucleoside analogues to peg-IFNα-2a enhances virological response in chronic hepatitis B patients without early response to peg-IFNα-2a: a randomized controlled trial.
    Xu Y; Wang X; Liu Z; Zhou C; Qi W; Jiao J; Yu F; Guo H; Zhao P; Wang J
    BMC Gastroenterol; 2017 Aug; 17(1):102. PubMed ID: 28854883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Interferon in hepatitis B].
    García Buey L; González Mateos F; Moreno Otero R
    Enferm Infecc Microbiol Clin; 2008 May; 26 Suppl 7():19-31. PubMed ID: 19100228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of viral hepatitis B.
    Pramoolsinsup C
    J Gastroenterol Hepatol; 2002 Feb; 17 Suppl():S125-45. PubMed ID: 12000599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The future of liver transplantation for viral hepatitis.
    Durand F; Francoz C
    Liver Int; 2017 Jan; 37 Suppl 1():130-135. PubMed ID: 28052618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients.
    Hung CH; Lu SN; Wang JH; Hu TH; Chen CH; Huang CM; Lee CM
    Antivir Ther; 2011; 16(7):959-68. PubMed ID: 22024511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Entecavir: a review of its use in the treatment of chronic hepatitis B in patients with decompensated liver disease.
    Keating GM
    Drugs; 2011 Dec; 71(18):2511-29. PubMed ID: 22141390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues?
    Viganò M; Mangia G; Lampertico P
    Liver Int; 2014 Feb; 34 Suppl 1():120-6. PubMed ID: 24373088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prophylaxis and treatment of recurrent viral hepatitis after liver transplantation.
    Riediger C; Berberat PO; Sauer P; Gotthardt D; Weiss KH; Mehrabi A; Merle U; Stremmel W; Encke J
    Nephrol Dial Transplant; 2007 Sep; 22 Suppl 8():viii37-viii46. PubMed ID: 17890261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nucleos(t)ide analogs in the prevention of hepatitis B virus related hepatocellular carcinoma.
    Baran B
    World J Hepatol; 2015 Jul; 7(13):1742-54. PubMed ID: 26167247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of HBV and HBV/HDV-Associated Liver Cirrhosis.
    Höner Zu Siederdissen C; Cornberg M
    Visc Med; 2016 Apr; 32(2):86-94. PubMed ID: 27413725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does antiviral therapy for hepatitis B and C prevent hepatocellular carcinoma?
    Lok AS
    J Gastroenterol Hepatol; 2011 Feb; 26(2):221-7. PubMed ID: 21070361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of hepatitis B virus genotypes B and C among chronically hepatitis B virus-infected patients who received nucleos(t)ide analogs: A multicenter retrospective study.
    Inoue J; Akahane T; Nakayama H; Kimura O; Kobayashi T; Kisara N; Sato T; Morosawa T; Izuma M; Kakazu E; Ninomiya M; Iwata T; Takai S; Nakamura T; Sano A; Niitsuma H; Masamune A;
    Hepatol Res; 2019 Nov; 49(11):1263-1274. PubMed ID: 31254482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.